2022 World Conference on Lung Cancer (Posters)-P1.16-03. Managing Cardiotoxicity in Metastatic Non-Small Cell Lung Cancer Patients Treated with Tyrosine Kinase Inhibitors (TKIs)

P1.16-03. Managing Cardiotoxicity in Metastatic Non-Small Cell Lung Cancer Patients Treated with Tyrosine Kinase Inhibitors (TKIs)

Back to course

Pdf Summary

Tyrosine kinase inhibitors (TKIs) used in the treatment of non-small cell lung cancer (NSCLC) have been associated with cardiotoxicity, including decreased left ventricular ejection fraction, QT prolongation, hypertension, bradycardia, myocarditis, and edema. However, there is currently insufficient evidence to support specific surveillance strategies for TKIs alone. In this study, the authors aimed to determine the current practice for screening and monitoring cardiotoxicity in NSCLC patients treated with TKIs, analyze adherence to recommended standards of care, and develop an institutional guideline for screening and monitoring.<br /><br />The study involved a retrospective chart review of 113 NSCLC patients treated with TKIs between August 2019 and August 2021. The findings showed that cardiotoxicity occurred in 40.7% of patients, with hypertension and bradycardia being the most frequent complications. Adherence to screening and monitoring standards was reported at 54%, but there was no significant relationship between adherence and cardiotoxicity.<br /><br />The study also highlighted the need for clearer guidelines and collaboration in cardio-oncology to mitigate cardiotoxic events. Recommendations included baseline and subsequent monitoring, dose adjustments, reduction schedules, and a list of drugs known to cause QT prolongation.<br /><br />Limitations of the study included missing data on echocardiograms and electrocardiograms. Future research should address these limitations and further investigate the incidence and management of cardiotoxicity associated with TKIs in NSCLC patients.<br /><br />Understanding the extent of cardiotoxicity and establishing clear guidelines for screening and monitoring can help mitigate the risks of cardiac complications in NSCLC patients receiving TKIs. Collaboration between oncologists and cardiologists is essential in managing and preventing cardiotoxic events. Further research is needed to optimize surveillance and management strategies for cardiotoxicity in this patient population.

Asset Subtitle

Luis Raez, United States

Meta Tag

Speaker Luis Raez, United States

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

Tyrosine kinase inhibitors

TKIs

non-small cell lung cancer

NSCLC

cardiotoxicity

left ventricular ejection fraction

QT prolongation

hypertension

bradycardia

myocarditis